The Journal of Contemporary Dental Practice

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 20 , ISSUE 8 ( August, 2019 ) > List of Articles


Expression of Yes-associated Protein in Oral Squamous Cell Carcinoma

Pankaj Shelke, Ghevaram Prajapati

Keywords : Oral cancer, Oral squamous cell carcinoma, Prognostic marker, Yes-associated protein

Citation Information : Shelke P, Prajapati G. Expression of Yes-associated Protein in Oral Squamous Cell Carcinoma. J Contemp Dent Pract 2019; 20 (8):887-892.

DOI: 10.5005/jp-journals-10024-2633

License: CC BY-NC 4.0

Published Online: 01-12-2019

Copyright Statement:  Copyright © 2019; The Author(s).


Aim: Though the exact mechanism of yes-associated protein (YAP) in tumorigenesis is not well understood, studies have shown that YAP plays an imperative role in cancer advancement via the Hippo signaling pathway. The purpose of the present study was to appraise the clinicopathological correlation of YAP expression in various grades and stages along with different parameters like tumor size and nodal metastasis in oral squamous cell carcinoma (OSCC). Materials and methods: Twenty-seven surgically excised specimens from patients with OSCC were selected for the study. Grading of the OSCC specimens was done according to Broder's grading system and staging had been done using tumor-node-metastasis (TNM) system by American Joint Committee on Cancer (AJCC). Comparative analysis of YAP expression and various aforementioned parameters of OSCC was performed and statistically analyzed. Results: Differences in the expression of YAP was observed among well differentiated and moderately differentiated OSCC, with increased YAP expression with successive grades but was statistically insignificant. On evaluating YAP expression among various stages of OSCC, we observed that stages I, II, and IV demonstrated a weak expression of YAP, while stage III showed a strong expression but the differences were insignificant. Insignificant differences were also noted in YAP expression between different tumor sizes, while significant differences were observed between different nodal statuses. Conclusion: Our results suggest that YAP could be responsible for extensive proliferation and invasiveness of OSCC.

  1. Elango JK, Gangadharan P, et al. Trends of head and neck cancers in urban and rural India. Asian Pac J Cancer Prev 2006;7(1):108–112.
  2. Sankaranarayanan R, Ramadas K, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005;365(9475):1927–1933. DOI: 10.1016/S0140-6736(05)66658-5.
  3. Manoharan N, Tyagi BB, et al. Cancer incidences in rural Delhi—2004–05. Asian Pac J Cancer Prev 2010;11(1):73–78.
  4. Joshi P, Dutta S, et al. Head and neck cancers in developing countries. Rambam Maimonides Med J 2014;5(2):e0009. DOI: 10.5041/RMMJ.10143.
  5. Hiemer SE, Zhang L, et al. A YAP/TAZ-Regulated molecular signature is associated with oral squamous cell carcinoma. Mol Cancer Res 2015;13(6):957–968. DOI: 10.1158/1541-7786.MCR-14-0580.
  6. Harvey K, Tapon N. The Salvador-Warts-Hippo pathway: An emerging tumor-suppressor network. Nat Rev Cancer 2007;7(3):182–191. DOI: 10.1038/nrc2070.
  7. Harvey KF, Pfleger CM, et al. The Drosophila Mstortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 2003;114(4):457–467. DOI: 10.1016/S0092-8674(03)00557-9.
  8. Huang J, Wu S, et al. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005;122(3):421–434. DOI: 10.1016/j.cell.2005.06.007.
  9. Zhao B, Ye X, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008;22(8):1962–1971. DOI: 10.1101/gad.1664408.
  10. Moroishi T, Hansen CG, et al. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 2015;15(2):73–79. DOI: 10.1038/nrc3876.
  11. Holden JK, Cunningham CN. Targeting the hippo pathway and cancer through the TEAD family of transcription factors. Cancers (Basel) 2018;10(3):81. DOI: 10.3390/cancers10030081.
  12. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014;13(1):63–79. DOI: 10.1038/nrd4161.
  13. Watson KL, Justice RW, et al. Drosophila in cancer research: the first fifty tumor suppressor genes. J Cell Sci 1994;18:19–33. DOI: 10.1242/jcs.1994.Supplement_18.4.
  14. Halder G, Johnson RL. Hippo signaling: Growth control and beyond. Development 2011;138(1):9–22. DOI: 10.1242/dev.045500.
  15. Lai D, Ho KC, et al. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011;71(7):2728–2738. DOI: 10.1158/0008-5472.CAN-10-2711.
  16. Guo L, Teng L. YAP/TAZ for cancer therapy: opportunities and challenges. Int J Oncol 2015;46(4):1444–1452. DOI: 10.3892/ijo.2015.2877.
  17. Zhang L, Ye D, et al. Yes-associated protein promotes cell proliferation by activating Fos Related Activator-1 in oral squamous cell carcinoma. Oral Oncol 2011;47(8):693–697. DOI: 10.1016/j.oraloncology.2011.06.003.
  18. Yuan M, Tomlinson V. Yes-associated protein (YAP) functions as tumor suppressor in Breast. Cell Death Differ 2008;15(11):1752–1759. DOI: 10.1038/cdd.2008.108.
  19. Ge L, Smail M, et al. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. Plos One 2011;6(11):e27529. DOI: 10.1371/journal.pone.0027529.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.